Subscribe to RSS
DOI: 10.1055/s-0043-1773542
Development of an Efficient Synthesis toward a 4,4-Difluoropiperidine Intermediate Bearing a Pyridine N-Oxide Motif at the Carbon Stereocenter

Abstract
The synthesis of a 4,4-difluoropiperidine intermediate, a key component of an MRGPRX2 antagonist, is challenging due to the presence of a gem-difluoro moiety adjacent to a stereocenter which also bears a reactive pyridine N-oxide motif. The initial discovery chemistry route required chiral supercritical fluid chromatography (SFC) at the end of the synthesis to provide enantiopure product. XtalFluor-E was used for deoxyfluorination on a ketone adjacent to a p-pyridylmethyl position, resulting in very low yields due to the elimination of HF. After several unsuccessful attempts for a de novo asymmetric synthesis, we focused our attention on the process development for a more practical synthesis than the existing route. A much higher yielding deoxyfluorination was enabled by SF4 and HF. Furthermore, the chiral SFC was replaced by an efficient classical resolution at a much earlier stage of the synthesis, taking advantage of the basicity of the pyridine moiety before oxidation to the pyridine N-oxide. Although not all stages have been scaled up in the plant scale, the new synthesis is much more practical and has improved the overall yield from 12% to 23% for this challenging molecule.
Key words
pyridine N-oxides - gem-difluoropiperidine synthesis - classical resolution - deoxyfluorination of ketone - MRGPRX2 antagonistSupporting Information
- Supporting information for this article is available online at https://doi.org/10.1055/s-0043-1773542.
- Supporting Information
Publication History
Received: 18 February 2025
Accepted after revision: 01 April 2025
Article published online:
17 April 2025
© 2025. Thieme. All rights reserved
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1a Abdelshaheed MM, Fawzy IM, El-Subbagh HI, Youssef KM. Future J. Pharm. Sci. 2021; 7: 188
- 1b Frolov NA, Vereshchagin AN. Int. J. Mol. Sci. 2023; 24: 2937
- 1c Lovering F, Bikker J, Humblet C. J. Med. Chem. 2009; 52: 6752
- 2a Kobus M, Friedrich T, Zorn E, Burmeister N, Maison W. J. Med. Chem. 2024; 67: 5168
- 2b Mfuh AM, Larionov OV. Curr. Med. Chem. 2015; 22: 2819
- 2c Sabnis RW. ACS Med. Chem. Lett. 2022; 13: 1006
- 3a Lumeras W, Caturla F, Vidal L, Esteve C, Balagué C, Orellana A, Domínguez M, Roca R, Huerta JM, Godessart N, Vidal B. J. Med. Chem. 2009; 52: 5531
- 3b Lumeras W, Vidal L, Vidal B, Balagué C, Orellana A, Maldonado M, Domínguez M, Segarra V, Caturla F. J. Med. Chem. 2011; 54: 7899
- 4a Pettersson M, Hou X, Kuhn M, Wager TT, Kauffman GW, Verhoest PR. J. Med. Chem. 2016; 59: 5284
- 4b Inoue M, Sumii Y, Shibata N. ACS Omega 2020; 5: 10633
- 4c Gillis EP, Eastman KJ, Hill MD, Donnelly DJ, Meanwell NA. J. Med. Chem. 2015; 58: 8315
- 5 Chen H, Gurung SR, Nieves-Quinones Y, Hruszkewycz DP, Nilson MG, Jakka K, Yin K, Hawkins BR, Splaine KJ, Slepian HA, Xie S. J. Org. Chem. 2024; 89: 17408
- 6 Brnardic E, Bury M, Cadilla R, Collins J, Guo Y, Handlon A, Li H, Li Y, Paone D, Schulte C, Shearer B, Ye G, Ying M, Zhang H. WO2022073904A1, 2022
- 7a Aggarwal T, Sushmita, Verma AK. Org. Chem. Front. 2021; 8: 6452
- 7b Ishii S, Niwa Y, Watanabe S. J. Fluorine Chem. 2016; 182: 41
- 7c Chernykh AV, Melnykov KP, Tolmacheva NA, Kondratov IS, Radchenko DS, Daniliuc CG, Volochnyuk DM, Ryabukhin SV, Kuchkovska YO, Grygorenko OO. J. Org. Chem. 2019; 84: 8487
- 7d Trofymchuk S, Bugera M, Klipkov AA, Ahunovych V, Razhyk B, Semenov S, Boretskyi A, Tarasenko K, Mykhailiuk PK. J. Org. Chem. 2021; 86: 12181
- 8 Wang X, Kolesnikov A, Tay S, Chan G, Chao Q, Do S, Drummond J, Ebens AJ, Liu N, Ly J, Harstad E, Hu H, Moffat J, Munugalavadla V, Murray J, Slaga V, Tsui V, Volgraf M, Wallweber H, Chang JH. J. Med. Chem. 2017; 60: 4458
- 9 Trofymchuk SA, Kliukovskyi DV, Semenov SV, Khairulin AR, Shevchenko VO, Bugera MY, Tarasenko KV, Volochnyuk DM, Ryabukhin SV. Synlett 2020; 31: 565
- 10 For the HTS of the classical resolution, we followed the protocol as described in: Tan H, Cui S, Gahm K, Luu V, Walke SD. Org. Process Res. Dev. 2011; 15: 53
- 11 Unsuccessful combinations did not yield solids in the reactive crystallization. See the Supporting Information for a full list of chiral acids and solvents.
- 12 The Boc deprotection with various sulfonic acids was successful for isolation of 1 as a crystalline salt of the sulfonic acids. However, those salts did not perform as efficiently as the free base 1 in the downstream chemistr
- 13 For an example of deoxyfluorination using SF4 in flow chemistry, see: Polterauer D, Wagschal S, Bersier M, Bovino C, Roberge DM, Hone CA, Kappe CO. Org. Process Res. Dev. 2024; 28: 2919
For reviews, see: